Attovia director granted 27,000 stock options

Q: What did Angie You report in this Form 4 for ATTO?

Angie You reported a grant of stock options for 27,000 shares of Attovia Therapeutics common stock, with an exercise price of $17.00 and an expiration date of August 3, 2036.

Q: What is the exercise price of the options granted to Angie You at ATTO?

The stock options granted to Angie You carry an exercise price of $17.00 per share. Each option allows purchase of one share of Attovia Therapeutics common stock at this price before expiration.

Q: How many Attovia Therapeutics (ATTO) options does Angie You hold after this grant?

After this reported transaction, Angie You holds 27,000 stock options directly from this award. These options are exercisable into an equal number of Attovia Therapeutics common shares once vested.

Q: When do Angie You’s Attovia (ATTO) options vest?

The options will fully vest on the earlier of August 4, 2027 or the next annual meeting of stockholders, conditioned on Angie You’s continued service to Attovia Therapeutics through that date.

Q: What is the expiration date of Angie You’s ATTO stock options?

The stock options granted to Angie You are set to expire on August 3, 2036. They must be exercised, if at all, on or before this expiration date, subject to the vesting conditions.

Attovia Therapeutics director Angie You received a grant of stock options for 27,000 shares of common stock.

Accepted by SEC EDGAR 08/06/2026 - 05:17 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Attovia Therapeutics director Angie You received a grant of stock options for 27,000 shares of common stock. The options have an exercise price of $17.00 per share and expire on August 3, 2036. According to the terms, the options vest in full on the earlier of August 4, 2027 or the next annual stockholders’ meeting, subject to continued service. Following this grant, the reported derivative holdings from this award total 27,000 options held directly.

Insider Trade Summary

Grant/Award: 27,000 shares

Grant/Award 1 txn

Insider You Angie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	27,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 27,000 contracts (Direct)

Footnotes (1)

F1. The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date.

Key Figures

Options Granted: 27,000 options Exercise Price: $17.00 per share Expiration Date: August 3, 2036 +2 more

5 metrics

Options Granted 27,000 options Stock Option (Right to Buy) award reported for August 4, 2026

Exercise Price $17.00 per share Conversion or exercise price of granted stock options

Expiration Date August 3, 2036 Expiration of the reported stock option grant

Underlying Shares 27,000 shares Common stock underlying the granted stock options

Vesting Outside Date August 4, 2027 Latest date for full vesting, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-08-03"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The options shall fully vest on the earlier of (i) August 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Angie You report in this Form 4 for ATTO?

Angie You reported a grant of stock options for 27,000 shares of Attovia Therapeutics common stock, with an exercise price of $17.00 and an expiration date of August 3, 2036.

What is the exercise price of the options granted to Angie You at ATTO?

The stock options granted to Angie You carry an exercise price of $17.00 per share. Each option allows purchase of one share of Attovia Therapeutics common stock at this price before expiration.

How many Attovia Therapeutics (ATTO) options does Angie You hold after this grant?

After this reported transaction, Angie You holds 27,000 stock options directly from this award. These options are exercisable into an equal number of Attovia Therapeutics common shares once vested.

When do Angie You’s Attovia (ATTO) options vest?

The options will fully vest on the earlier of August 4, 2027 or the next annual meeting of stockholders, conditioned on Angie You’s continued service to Attovia Therapeutics through that date.

What is the expiration date of Angie You’s ATTO stock options?

The stock options granted to Angie You are set to expire on August 3, 2036. They must be exercised, if at all, on or before this expiration date, subject to the vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

You Angie

(Last)

(First)

(Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17	08/04/2026		A		27,000		⁽¹⁾	08/03/2036	Common Stock	27,000	$0	27,000	D

Explanation of Responses:

1. The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date.

	/s/ Steven Chan, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR